Click Here for 5% Off Your First Aladdin Purchase!

Batimastat - ≥98%, high purity , CAS No.130370-60-4, Inhibitor of MMP1;Inhibitor of MMP13;Inhibitor of MMP3

Specifications & Purity:  ≥98%
Item Number
B125646
Grouped product items
SKUSizeAvailabilityPrice Qty
B125646-1mg
1mg
In stock
$33.90
B125646-5mg
5mg
In stock
$137.90
B125646-25mg
25mg
In stock
$434.90

Potent, broad-spectrum MMP inhibitor

Basic Description

Synonymsbatimastat|130370-60-4|BB-94|Batimastat (BB-94)|BB94|BB 94|Batimastat (MMP Inhibitor)|Batimastat(BB-94)|Butanediamide, N4-hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]-, (2R,3S)-|CHEMBL279786|(2
Specifications & Purity≥98%
Storage TempStore at -20°C
Shipped InDry ice
Action TypeINHIBITOR
Mechanism of actionInhibitor of MMP1;Inhibitor of MMP13;Inhibitor of MMP3

Associated Targets

FCER2 Tchem Low affinity immunoglobulin epsilon Fc receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MMP1 Tchem Interstitial collagenase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MMP7 Tchem Matrilysin 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MMP13 Tchem Collagenase 3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MMP14 Tchem Matrix metalloproteinase-14 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MMP9 Tchem Matrix metalloproteinase-9 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MMP2 Tchem 72 kDa type IV collagenase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADAM17 Tchem Disintegrin and metalloproteinase domain-containing protein 17 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MMP3 Tchem Stromelysin-1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Pubchem Sid488195427
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488195427
IUPAC Name (2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide
INCHI InChI=1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)/t17-,18+,19+/m1/s1
InChi Key XFILPEOLDIKJHX-QYZOEREBSA-N
Canonical SMILES CC(C)CC(C(CSC1=CC=CS1)C(=O)NO)C(=O)NC(CC2=CC=CC=C2)C(=O)NC
Isomeric SMILES CC(C)C[C@H]([C@H](CSC1=CC=CS1)C(=O)NO)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NC
WGK Germany 3
PubChem CID 5362422
Molecular Weight 477.64

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

7 results found

Lot NumberCertificate TypeDateItem
K1813128Certificate of AnalysisApr 02, 2024 B125646
B2317336Certificate of AnalysisJan 06, 2023 B125646
B2317341Certificate of AnalysisJan 06, 2023 B125646
B2317342Certificate of AnalysisJan 06, 2023 B125646
B2317366Certificate of AnalysisJan 06, 2023 B125646
B2317376Certificate of AnalysisJan 06, 2023 B125646
K1813127Certificate of AnalysisJul 18, 2022 B125646

Chemical and Physical Properties

SolubilityDMSO 96 mg/mL Water <1 mg/mL Ethanol <1 mg/mL

Safety and Hazards(GHS)

Related Documents

References

1. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A et al..  (1996)  Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer..  Invest New Drugs,  14  (2): (193-202).  [PMID:8913840]
2. Parsons SL, Watson SA, Steele RJ.  (1997)  Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites..  Eur J Surg Oncol,  23  (6): (526-31).  [PMID:9484924]
3. Beattie GJ, Smyth JF.  (1998)  Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites..  Clin Cancer Res,  (8): (1899-902).  [PMID:9717817]
4. Oda SK et al..  (2020)  A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy..  J Exp Med,  217  (12):   [PMID:32860705]
5. Paschkowsky S et al..  (2016)  Alternative Processing of the Amyloid Precursor Protein Family by Rhomboid Protease RHBDL4..  J Biol Chem,  291  (42): (21903-21912).  [PMID:27563067]
6. McColl R et al..  (2016)  Analysis and quantification of in vitro myoblast fusion using the LADD Multiple Stain..  Biotechniques,  61  (6): (323-326).  [PMID:27938324]
7. Cremasco V et al..  (2014)  B cell homeostasis and follicle confines are governed by fibroblastic reticular cells..  Nat Immunol,  15  (10): (973-81).  [PMID:25151489]
8. Beltramo E et al..  (2014)  Extracellular vesicles derived from mesenchymal stem cells induce features of diabetic retinopathy in vitro..  Acta Diabetol,  51  (6): (1055-64).  [PMID:25374383]
9. Ambite I et al..  (2016)  Molecular Basis of Acute Cystitis Reveals Susceptibility Genes and Immunotherapeutic Targets..  PLoS Pathog,  12  (10): (e1005848).  [PMID:27732661]
10. Keppie SJ et al..  (2021)  Matrix-Bound Growth Factors are Released upon Cartilage Compression by an Aggrecan-Dependent Sodium Flux that is Lost in Osteoarthritis..  Function (Oxf),  (5): (zqab037).  [PMID:34423304]

Solution Calculators